The US Meals and Drug Administration mentioned a tv commercial for Novo Nordisk’s weight-loss pill is “false or misleading,” in line with a letter dated February 5.
The well being regulator mentioned the tv spot misleadingly means that Wegovy, in its pill type, provides an development or enchancment over different weight-loss medication that belong to the category often known as GLP-1s.
“We affirm that Novo Nordisk obtained an ‘Untitled Letter’ from FDA regarding a tv industrial for Wegovy pill, which has been working since launch — not the Tremendous Bowl ad,” mentioned Novo spokeswoman Ambre James-Brown. The company mentioned the Novo direct-to-consumer ad was in violation of the Federal Meals, Drug, and Beauty Act, and requested the drugmaker to take instant motion to handle any violations, which might embody ceasing all advertisements containing misleading claims.
“We take all regulatory suggestions critically and are within the course of of responding to the FDA to handle their considerations relating to the commercial’s presentation,” James-Brown added.
The FDA additionally mentioned the claims “reside lighter” and “a method ahead” misleadingly suggest extra weight reduction in comparison with different at present permitted GLP-1 remedies, when this has not been demonstrated.
“Moreover, they misleadingly suggest advantages past bodily weight reduction, comparable to emotional reduction, decreased psychological burden, hope, or route for sufferers’ lives, positioning the drug as an answer to broader life challenges somewhat than a remedy for a particular situation, when this has additionally not been demonstrated,” the company mentioned within the letter.
The FDA additionally flagged the ad included sure shows the place the textual content on display screen didn’t match the audio.
Printed on February 10, 2026
Source link
#FDA #Novos #obesity #pill #false #misleading
